Structural bioinformatics-based identification of putative plant based lead compounds for Alzheimer Disease Therapy |
| |
| Institution: | 1. School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China;2. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China;3. Yangtze River Pharmaceutical (Group) Co., Ltd, Taizhou 225300, People’s Republic of China;4. China-Japan Research Institute of Medical Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China;5. School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China;1. Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, United States;2. Computational Genomics Department, National Institute of Genomic Medicine (INMEGEN), Mexico;3. Centro de Ciencias de la Complejidad, Universidad Nacional Autónoma de México (UNAM), Mexico;4. Inorganic Chemistry Department, Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Mexico;1. School of Electrical and Information Engineering, Anhui University of Technology, 243032 Ma’anshan, Anhui, China;2. Institutes of Physical Science and Information Technology, Anhui University, 230601 Hefei, Anhui, China |
| |
| Abstract: | Plant based lead compounds have been historically incredible as a source of therapeutic agents for various complex disorders including Alzheimer’s disease (AD). AD is one of the leading neurodegenerative disorder in which the underlying risk factors remain largely unclear and presently, there is no disease modifying treatment available. Despite its potential, to date only few compounds have entered for clinical trials. Herein, we described the identification of plant based lead compounds for treatment of AD through an integrative approach of pharmacokinetics and structure bioinformatics approach. In particular we performed screening of lead compounds from 3 traditional medicinal plants namely Withania somnifera, Bacopa monnieri and Morus alba, which are known to have potential for treatment of neurodegenerative disease. We retrieved a total of 210 plant based compounds of which 21 compounds were screened based on their pharmacokinetic properties. Further, Docking study against 7 known AD associated targets were carried out to identify the binding sites and direct interacting residues. In addition we investigate the stable and reliable binding mechanism of top such plant compounds against 3 targets through molecular docking followed by Molecular Dynamic(MD) simulation. The results obtained in the study revealed that 3 drug compounds namely Morusin (MRSN), Withanone (WTHN) and 27-Hydroxywithanolide B (HWTHN) were identified as putative lead compounds against mono amine oxidase (MAOB), Beta-secretase 1(BACE1) and phosphodiesterase 4D. |
| |
| Keywords: | Plant-base lead compounds Pharmacokinetics Docking Binding sites Molecular dynamic simulation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
